Hemorrhagic Cerebellar Anaplastic Glioma Appearing 12 Years After Prophylactic Cranial Radiotherapy for Acute Lymphocytic Leukemia  -Case Report-

Miyazawa, Takahito; Aida, Shinsuke; Shima, Katsuji

doi:10.2176/nmc.48.126

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Worse, radiotherapy might convert the tumor into an aggressive squamous cell carcinoma 21. However, some authors have reported that no cell anaplasia was observed in patients treated with radiotherapy, and only 7% of patients treated with radiotherapy exhibit cell anaplasia 29,30. Some patients who were treated with surgery but not radiotherapy still exhibited similar anaplasia.…”

Section: Discussionmentioning

confidence: 99%

An individual drug-therapy and genetic testing report of temporal bone verrucous carcinoma

Tan¹,

Liu²,

Zhu³

et al. 2014

OTT

View full text Add to dashboard Cite

ObjectiveTo investigate the pathology and pathogenesis of and treatment methods for temporal bone verrucous carcinoma.Materials and methodsA single-patient report of verrucous carcinoma on the left external auditory canal is presented and analyzed along with all cases of temporal bone verrucous carcinoma that have been documented in the English literature.ResultsMost of the patients with verrucous carcinoma of the temporal bone have histories of surgery, trauma, or infection, and verrucous carcinomas are sensitive to antimicrotubule chemotherapeutic medicines. Adjuvant radiation therapy is not effective, but surgical treatment might be relatively more effective.ConclusionTemporal bone verrucous carcinoma has a poor prognosis; therefore, the preferred treatment is surgical resection facilitated with antimicrotubule chemotherapeutic treatment. Adjuvant radiation therapy is not a preferred treatment for temporal bone verrucous carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

An individual drug-therapy and genetic testing report of temporal bone verrucous carcinoma

Tan¹,

Liu²,

Zhu³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

Secondary glioma following acute lymphocytic leukemia: therapeutic implications

Yamanaka

Hayano

2016

Neurosurg Rev

View full text Add to dashboard Cite

We conducted a comprehensive review of the literature to characterize the etiology of secondary glioma following acute lymphocytic leukemia (ALL) patients. The analysis included 98 cases with an average age of onset of ALL of 5.9 years (range 1.5 to 26). The average latency period was 7.8 years until diagnosis of secondary glioma. Radiation therapy was administered in 92 cases for the primary malignancy at an average dose of 20.7 Gy. The median survival time of patients treated with multimodality treatment for secondary glioma was 23 months (95 % confidence interval 12-27 months), and multimodality therapy improved survival time significantly (p = 0.0029). The exact cause for the development of glioma following ALL is not clear. The risk of a secondary glioma in childhood cancer survivors may be influenced by genetic and other predisposing factors as well as by treatment type. In patients diagnosed with ALL, the risk of secondary glioma warrants a longer follow-up period that continues long after the risk of relapse of the primary malignancy has passed. Moreover, multimodality therapy should be considered in cases of secondary glioma following ALL.

show abstract

Radiation-induced gliomas: a comprehensive review and meta-analysis

2016

View full text Add to dashboard Cite

By conducting a systemic search of the PubMed database, we performed a comprehensive literature review to characterize secondary gliomas following radiotherapy treatment and to determine the most appropriate treatment strategy. Our analysis included 296 cases of radiation-induced gliomas. The primary lesion was characterized as a hematological malignancy in 104 cases (35.1 %), pituitary adenoma in 35 (11.8 %), craniopharyngioma in 19 (6.4 %), medulloblastoma in 38 (12.8 %), germ cell tumor in 13 (4.3 %), low-grade glioma in 28 (9.4 %), cancer/sarcoma in 12 (4.0 %), scalp region disease in 15 (5.0 %), meningioma/schwannoma in 13 (4.3 %), metastatic brain tumor in 5 (1.6 %), and other types (e.g., arteriovenous malformations and angiomas) in 14 (4.7 %). The average age of onset for primary lesions was 16.0 ± 15.8 years, and the average radiation dose delivered to the primary lesion was 37.6 ± 20.0 Gy. Secondary gliomas could be divided into grade I (1), grade II (32), grade III (88), and grade IV (173) tumors. The median overall survival for all glioma cases was 11 months (95 % confidence interval [CI], 9-12), with a 2-year survival rate of 20.2 %. On multivariate analysis, combined modality treatment and the latency period from the radiotherapy treatment to the glioma diagnosis were variables associated with the overall survival of patients with grade III/IV secondary gliomas. For patients treated with cranial radiotherapy, the risk of secondary glioma incidence warrants a longer follow-up period beyond the standard time frame typically designated for determining the risk of primary tumor relapse. Moreover, combination therapy is a potential treatment option for radiation-induced gliomas.

show abstract

Hemorrhagic Cerebellar Anaplastic Glioma Appearing 12 Years After Prophylactic Cranial Radiotherapy for Acute Lymphocytic Leukemia -Case Report-

Cited by 4 publications

References 20 publications

An individual drug-therapy and genetic testing report of temporal bone verrucous carcinoma

An individual drug-therapy and genetic testing report of temporal bone verrucous carcinoma

Secondary glioma following acute lymphocytic leukemia: therapeutic implications

Radiation-induced gliomas: a comprehensive review and meta-analysis

Contact Info

Product

Resources

About